We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Beats Earnings and Sales in Q3, Tweaks View
Read MoreHide Full Article
Abbott (ABT - Free Report) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments – namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. However, unfavorable movement in foreign currency rates is affecting the top line adversely.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4.6%.
Currently, Abbott Labs has a Zacks Rank #2 (Buy), but that could definitely change following the company’s third quarter 2017 earnings report which was just released. (You can seethe complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The Zacks Consensus Estimate remained steady at 65 cents per share over the last 60 days. Abbott’s third quarter 2017 earnings per share from continuing operations of 66 cents outpaced this estimate by a penny.
Revenues: Abbott Labs posted third quarter revenues of $6.82 billion surpassing behind the Zacks Consensus Estimate for revenues of $6.71 billion.
Key Stats: Worldwide Nutrition sales increased 0.8% on a reported basis in the third quarter to $1.76 billion while worldwide Diagnostics sales increased 5.4% on a reported basis to $1.27 billion while total Established Pharmaceuticals sales increased 15.7% on a reported basis to $1.17 billion. Revenues of Worldwide Medical Devices increased 98.2% on a reported basis to $2.59 billion.
Major Factors: Per management, Abbott’s third quarter results reflect a strong performance. The company is well positioned to achieve the upper end of the initial full-year EPS guidance range. Management narrowed its full-year 2017 EPS guidance which ranges from $2.48 to $2.50 now.The company has received many FDA approvals recently.
Stock Price: Following the earnings release, share prices rose 1.7% during the pre-market trading session.
Check back later for our full write up on this Abbott earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Abbott (ABT) Beats Earnings and Sales in Q3, Tweaks View
Abbott (ABT - Free Report) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments – namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. The company has reshaped its portfolio through strategic acquisitions/divestitures in recent times. It has also been taking strategic steps to expand its footprint in the growing geographies and investing in R&D, which has resulted in numerous new product launches across its businesses.
In Feb 2015, Abbott completed the sale of its branded generics pharmaceuticals business in developed markets. Realignment of the EPD division through acquisitions in Latin America and Russia, along with business divestitures in developed markets, has positioned the company well for the coming quarters. However, unfavorable movement in foreign currency rates is affecting the top line adversely.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 4.6%.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
Currently, Abbott Labs has a Zacks Rank #2 (Buy), but that could definitely change following the company’s third quarter 2017 earnings report which was just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. ) We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: The Zacks Consensus Estimate remained steady at 65 cents per share over the last 60 days. Abbott’s third quarter 2017 earnings per share from continuing operations of 66 cents outpaced this estimate by a penny.
Revenues: Abbott Labs posted third quarter revenues of $6.82 billion surpassing behind the Zacks Consensus Estimate for revenues of $6.71 billion.
Key Stats: Worldwide Nutrition sales increased 0.8% on a reported basis in the third quarter to $1.76 billion while worldwide Diagnostics sales increased 5.4% on a reported basis to $1.27 billion while total Established Pharmaceuticals sales increased 15.7% on a reported basis to $1.17 billion. Revenues of Worldwide Medical Devices increased 98.2% on a reported basis to $2.59 billion.
Major Factors: Per management, Abbott’s third quarter results reflect a strong performance. The company is well positioned to achieve the upper end of the initial full-year EPS guidance range. Management narrowed its full-year 2017 EPS guidance which ranges from $2.48 to $2.50 now.The company has received many FDA approvals recently.
Stock Price: Following the earnings release, share prices rose 1.7% during the pre-market trading session.
Check back later for our full write up on this Abbott earnings report later!
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>